The paradigm shift from Non‐alcoholic Steatohepatitis (NASH) to Metabolic Dysfunction–associated Steatohepatitis (MASH) reflects a deeper understanding of the pathophysiology underpinning liver injury in the context of obesity, diabetes, and metabolic syndrome. This evolving nomenclature from NASH to MASH is more than a semantic update—it mirrors a fundamental change in how we conceptualize liver disease, moving away from a definition based solely on the exclusion of alcohol consumption toward one that highlights the central role of metabolic dysregulation.
The Nomenclature Evolution
Historically, liver conditions characterized by steatosis wit...
